Natalizumab Completed Phase 4 Trials for Disseminated Sclerosis

IndicationsStatusPurposePhase
CompletedNot Available4
clinicaltrials.gov IdentifierTitleDrugs
NCT00536120The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis